Answers are grounded in this paper and cite their sources.
Here we present a case of stage IIIB (cT3N2M0) lung squamous cell carcinoma, who was potentially resectable, and underwent a complete resection after three cycles of neoadjuvant therapy induced by sugemalimab combined with platinum-based doublet chemotherapy. The assessment of resected lung sample and lymph nodes has shown a pathological complete response in this case, although the radiographical response was stable. Potential biomarkers that may correlate with the efficacy were also explored in this case. A positive expression of PD-L1 level at baseline, and the clearance of tumor mutation burden via ctDNA after neoadjuvant regimens, as well as the varieties of tumor microenvironment shown as macrophage marker and PSMB-8, PSMB-9, PSMB-10, the immunoproteasome (IP) subunits, using the assay of multiple immunofluorescence and immunohistochemistry respectively, have all indicated the favorable and long-lasting effect of the combination strategy in the neoadjuvant setting.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: